BOLERO-4: A Phase 2, Open-Label, Multicenter, Single-Arm Trial Investigating The Efficacy And Safety Of First-Line Everolimus (Eve) In Combination With Letrozole (Let) In Postmenopausal Patients (Pts) With Estrogen Receptorpositive (Er plus ), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Metastatic Or Locally Advanced Unresectable Breast Cancer (Bc)